The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience.

#1294

Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib

Aim(s): evaluation efficacy and toxicity

Materials and methods: All pts received long acting somatostatin analogs.The mean age was 55 years, 4 male, 15 female. The most of pts had pancreatic neuroendocrine tumor – 16(84%)pts, kidney NET–1 pt,primary multiple synchronous panceatic+kidney had 2 patients.There was index proliferation Ki67% determination: Ki67 less 3% -1 pt, Ki67%= 3-20% had 15pts; ki67% more than 20% had 2pts. There were 3 pts with G1 NETs, 16 patients with G2 NETs.Cytoreductive surgery was performed in 9 -47,3%pts. 6/19 pts had 0-1-2 prior lines of CT and 13/19 patients were heavily pretreated with more than 3 lines of CT. Previous treatment included interferon α, octreotide LAR, XelOx, EP and of temozolomide, paclitaxel and fluoropyrimidines, everolimus. Sunitinib as a first line treatment was in 3 patients, after everolimus therapy was in 2 cases.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Odintsova A, Gorbunova V, Orel N, Markovich A, Kouzminov A,

Keywords: NET, sunitinib,efficacy,chemotherapy,